Regenxbio IncRGNX
Price$7.42

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $174.5M+109.4% YoYTTM through 30 Jun 2026
Net Income -$196.4MTTM through 30 Jun 2026
Free Cash Flow -$249.7MTTM through 30 Jun 2026

Margins

Current
EBITDA Margin-85.3%
Operating Margin-1,129.5%
Net Margin-112.6%

Returns

-84.8%ROA

Balance Sheet Health

Debt / Equity7.74x
Current Ratio1.12x
Net Debt$12.6M
Cash & Equivalents$36.5M

Quality Metrics

Altman Z-Score-3.77
Piotroski F-Score3 / 9
FCF Margin-143.1%
Rule of 40-106.8
Earnings-Beat Rate25.0%

Multi-Year Trend

Revenue
'19'20'21'22'23'24'25
FY2025: $170.4M
Diluted EPS-$3.78TTM
'19'20'21'22'23'24'25
FY2025: $-3.76

Dividend

No dividend

Capital Allocation

Capex Intensity1.7%
All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.